Tag Archives: Asklepios BioPharmaceutical

Bayer and Acuitas Therapeutics Join Forces for Targeted Gene Editing Delivery

Not intended for U.S. and UK Media (IN BRIEF) Bayer AG has partnered with Acuitas Therapeutics, Inc. to enhance its gene therapy portfolio. Acuitas’ lipid nanoparticle (LNP) delivery technology will enable targeted and efficient delivery of gene editing RNA components … Read the full press release

Bayer: Viralgen Vector Core Licensed for Large-Scale recombinant adeno-associated virus (rAAV) Gene Therapy Production

(PRESS RELEASE) SAN SEBASTIAN, Spain, 9-Jan-2023 — /EuropaWire/ — Bayer (ETR: BAYN), a global enterprise with core competencies in the life science fields of healthcare and nutrition and and one of the largest pharmaceutical companies in the world, has announced … Read the full press release

Bayer: Viralgen Vector Core con licencia para la producción de terapia génica de virus adenoasociados recombinantes (rAAV) a gran escala

(COMUNICADO DE PRENSA) SAN SEBASTIAN, Spain, 9-Jan-2023 — /EuropaWire/ — Bayer (ETR: BAYN), una empresa global con competencias básicas en los campos de las ciencias biológicas de la salud y la nutrición y una de las compañías farmacéuticas más grandes … Read the full press release